Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 2Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Neuroblastoma 1Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

pembrolizumab 23Nivolumab 20atezolizumab 10Specimen Handling 8Ipilimumab 8Cyclophosphamide 8cabozantinib 6Magnetic Resonance Spectroscopy 6fludarabine 5Sorafenib 5sargramostim 4Trastuzumab 4Sunitinib 4Bevacizumab 4lenvatinib 3enzalutamide 3durvalumab 3avelumab 3X-Rays 3Paclitaxel 3Fluorodeoxyglucose F18 3Docetaxel 3Albumin-Bound Paclitaxel 3ulixertinib 2spartalizumab 2relatlimab 2regorafenib 2palbociclib 2epacadostat 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Trabectedin × Genitourinary × Clear all
NCT01453283 2017-07-02

Tabectedin to Treat Children and Adolescents With Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
12 enrolled
CNSGastrointestinalGenitourinarySarcoma

Brain Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡